A recent study highlights a surprising potential benefit of diabetes and obesity drugs, GLP-1 receptor agonists, in improving ...

By Tarun Sai Lomte An expert editorial suggests that widely used diabetes and obesity drugs may help close the long-standing ...

Most patients receiving a GLP-1 receptor agonist (RA) and a biologic continue co-therapy for over a year with few treatment-related adverse events.

Although both sodium-glucose cotransporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) ...

LMNT reports that GLP-1 medications for obesity and diabetes may lead to electrolyte imbalances, highlighting hydration ...

FDA requests removal of suicidal ideation warnings from GLP-1 RA labels after meta-analysis shows no increased risk compared with placebo.

The researchers found that GLP-1 RA use was associated with significantly lower odds of vertebral compression fractures compared with nonuse. (HealthDay News) — Glucagon-like peptide 1 receptor ...

This randomized controlled trial shows that structured moderate-to-vigorous exercise, alone or combined with liraglutide, ...

GLP-1 drugs mimic the GLP-1 hormone in the body, which helps to treat type 2 diabetes and obesity. In India, GLP-1 RAs are ...

Patients with type 2 diabetes and inflammatory arthritis who received GLP-1 RAs had lower rates of hypoglycemia, serious infections, and acute kidney injury vs those receiving SGLT2 inhibitors.

GLP-1 RAs probably have little or no effect on risk for thyroid cancer, pancreatic cancer, breast cancer, or kidney cancer. HealthDay News — Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) seem ...

Odds of vertebral compression fractures or surgical intervention were significantly lower among GLP-1 RA users. (HealthDay News) — Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) may protect ...